Price Alert

Protalix BioTherapeutics ... (PLX)

AMEX: PLX · Real-Time Price · USD

1.54

-0.05 (-3.14%)

At close: Sep 05, 2025, 3:59 PM

1.55

0.32%

After-hours: Sep 05, 2025, 07:10 PM EDT

-3.14% (1D)

Bid	1.5
Market Cap	123.15M
Revenue (ttm)	61.95M
Net Income (ttm)	6.28M
EPS (ttm)	0.09
PE Ratio (ttm)	17.17
Forward PE	2.88
Analyst	Strong Buy

Ask	1.57
Volume	1,170,780
Avg. Volume (20D)	793,998
Open	1.59
Previous Close	1.59
Day's Range	1.52 - 1.60
52-Week Range	0.98 - 3.10
Beta	-0.23

About PLX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PLX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PLX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Protalix BioTherapeutics Inc. is scheduled to release its earnings on Nov 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

-40.48%

Protalix BioTherapeutics shares are trading lower ... Unlock content with Pro Subscription

5 months ago

+9.38%

Protalix BioTherapeutics shares are trading higher after the company reported a FY 2024 GAAP EPS beat.

News

1 week ago · seekingalpha.com

Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp

Protalix BioTherapeutics uses a plant-cell approach with ProCellEx. This has given it two approved ERTs plus PRX-115 and PRX-119. Its main focus is on a growing rare-disease pipeline. The main value d...

3 weeks ago · seekingalpha.com

Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (NYSE:PLX ) Q2 2025 Earnings Call August 14, 2025 8:30 AM ET Company Participants Dror Bashan - President, CEO & Director Eyal Rubin - Senior VP, CFO, Treasurer & Corpor...

3 weeks ago · proactiveinvestors.com

Protalix BioTherapeutics lifts revenue on strong Elfabrio demand

Protalix Biotherapeutics Inc (NYSE-A:PLX) reported higher quarterly revenue and reaffirmed its long-term growth outlook on Thursday, pointing to expanding demand for its Fabry disease treatment Elfabr...

1 month ago · proactiveinvestors.com

Protalix BioTherapeutics welcomes new finance chief

Protalix BioTherapeutics Inc (NYSE-A:PLX) has announced the appointment of Gilad Mamlok as senior vice president and chief financial officer, succeeding Eyal Rubin. Mamlok has already joined the compa...

2 months ago · proactiveinvestors.com

Protalix BioTherapeutics joins Russell 3000 and 2000 indexes following annual reconstitution

Protalix Biotherapeutics Inc (NYSE-A:PLX) announced that it has been added to the Russell 3000 and Russell 2000 Indexes, effective after the US market closed on Friday, June 27. The inclusion follows...